An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status.

Trial Profile

An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2018

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TAILOR
  • Sponsors Merck KGaA
  • Most Recent Events

    • 05 Jun 2018 Final overall survival results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 28 May 2018 Status changed from active, no longer recruiting to completed.
    • 12 Sep 2017 Results assessing Quality of life (QoL) from patients with RAS wild-type metastatic colorectal cancer (n=393) presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top